Research and Markets: Mexico Pharmaceuticals and Healthcare Report Q2 2010

Research and Markets (http://www.researchandmarkets.com/research/dc2c73/mexico_pharmaceuti) has announced the addition of the "Mexico Pharmaceuticals and Healthcare Report Q2 2010" report to their offering.

Business Monitor International's Mexico Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Mexico's pharmaceuticals and healthcare industry.

The total drug market in Mexico will increase from US$9.79bn in 2009 to US$18.96bn by 2014 at a compound annual growth rate (CAGR) of 14.1%. Thereafter the CAGR will slow to 7.6% to 2019, giving a final market value of US$27.48bn. Per-capita spending on medicines will be US$170 in 2014, up from US$91 in 2009, while the proportion of GDP dedicated to drug spending was 1.13% in 2009 and will reach 1.25% by 2014.

The US Food and Drug Administration (FDA) has opened a new representative office in Mexico City, the body's 3rd post in Latin America after those in Chile and Costa Rica. The presence of the FDA in Mexico should strengthen existing regulatory ties between the countries, particularly since bilateral trade is already a commonality.

BMI expects the FDA to be in close contact with Mexican authorities regarding food and medicine production in order to boost the safety of all products destined for the US, while also encouraging regulatory harmonisation and knowledge transfer. The decision to locate an FDA post in Mexico is part of a preventative strategy to ensure than sub-standard goods are not produced and distributed in the first place, let alone seized at border points with the US. The US government also asserts that this move is part its wider redesign of product safety strategy. In light of the current debate on whether medicines can be imported from a greater selection of countries, any successes in Mexico will highlight the advantages of increasing the presence of the FDA in developing countries.

The Mexican government is keen to improve its regulatory standards in order to increase trade with developed markets like its immediate neighbour. Pharmaceutical counterfeits and other negative publicity surrounding food products from Mexico have also made a US FDA post there a more attractive proposition.

Mexico's state-run health insurance scheme for those on low incomes or without other healthcare options, Seguro Popular, is intending to enroll an additional 12mn people in 2010 according to the health secretariat. In 2011, another 6mn people will be added to the scheme, giving a total of 18mn new additions and comprising the last remaining segment of the Mexican population eligible to be included in the programme.

Membership of Seguro Popular is voluntary, but the government is optimistic that everyone eligible will join, particularly since the majority of people targeted are on low incomes and cannot afford healthcare in any other way. At present, 88mn Mexicans have health insurance through the Mexican Social Security Institute (IMSS) or the Institute of Social Security Services (ISSSTE).

Key Topics Covered:

Executive Summary

SWOT Analysis

Pharmaceutical Business Environment Ratings

Mexico Market Summary

Regulatory Regime

Industry Developments

Industry Forecast Scenario

Company Profiles

Country Snapshot: Mexico Demographic Data

BMI Methodology

Companies Mentioned:

• Liomont
• Strides Latina (Solara)
• Genomma Labs
• Pfizer
• GlaxoSmithKline (GSK)
• Sanofi-Aventis
• Eli Lilly
• Bristol-Myers Squibb (BMS)
• Novartis Farmacutica
• Bayer
• Boehringer Ingelheim Promeco
• Merck KGaA
• Roche

For more information visit http://www.researchandmarkets.com/research/dc2c73/mexico_pharmaceuti